NEW
Stock Screener with Intrinsic Value
Vertex Pharmaceuticals Incorporated (VRTX)
Last Price$409.9(0.5%)
Market Cap$105.0B
LTM NOPAT
$580.3M
NOPAT margin
5.5%
5Y avg: 31.4%
EPV as % of EV
7.3%
Market-Implied Value of Growth,
MIVoG as % of EV
92.7%
Discount rate
6.9%
Stock quality
6/10
Good
VRTX Earnings Power Value Model
Crunching data... Almost there!
Best stock ideas on the market right now
With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.
VRTX NOPAT
Crunching data... Almost there!
VRTX Earnings Power Value and Enterprise Value
Crunching data... Almost there!
VRTX vs Peer Set: Earnings Power Value comparison
Crunching data... Almost there!
Explore more intrinsic value tools hub for VRTX
Reverse DCF
Intrinsic Value
Peter Lynch Fair Value
Discount rate
Earnings growth model
Relative Value
DCF value calculator
Ben Graham Fair Value
Peter Lynch charts
Margin of safety
Loved by
investors
worldwide
investors
worldwide
10K+
Investors
use our platform
#1
Top value investing hub
with all necessary tools
1K+
Experienced investors
in our community
4.9
Average rating across
all rating platforms
FAQ
What is Vertex Pharmaceuticals Incorporated Earnings Power Value?
As of Sep 30, 2024, Vertex Pharmaceuticals Incorporated's Earnings Power Value is approximately $8,386.1M.
What is Vertex Pharmaceuticals Incorporated EV (Enterprise Value)?
As of Sep 30, 2024, Vertex Pharmaceuticals Incorporated's Enterprise Value (EV) estimates at $115.5B.
What is Vertex Pharmaceuticals Incorporated NOPAT?
As of Sep 30, 2024, Vertex Pharmaceuticals Incorporated's Net operating profit after tax (NOPAT) is approximately $580.3M.